Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 130 entries
View as:

Phase I Study of the Combination of Apatinib and POF

Phase: N/A Priority: Normal
NCT ID: NCT03244774 Org: User:
Start: 01/01/18 End: 06/30/19 Due: 06/30/20

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT03375515 Org: User:
Start: 09/29/18 End: 01/10/20 Due: 01/10/21

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05648994 Org: User:
Start: 12/31/22 End: 03/31/26 Due: 03/31/27

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Phase: N/A Priority: Normal
NCT ID: NCT03030937 Org: User:
Start: 02/01/17 End: 12/30/18 Due: 12/30/19

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05223088 Org: User:
Start: 10/31/21 End: 04/30/24 Due: 04/30/25

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03788174 Org: User:
Start: 02/01/19 End: 12/31/20 Due: 12/31/21

MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06126393 Org: User:
Start: 01/01/24 End: 06/30/27 Due: 06/30/28

SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06979986 Org: User:
Start: 06/01/25 End: 04/01/27 Due: 04/01/28

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Phase: N/A Priority: Normal
NCT ID: NCT05897138 Org: User:
Start: 08/01/23 End: 06/01/27 Due: 06/01/28

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Phase: N/A Priority: Normal
NCT ID: NCT06490913 Org: User:
Start: 11/01/24 End: 12/31/25 Due: 12/31/26

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05595889 Org: User:
Start: 12/01/22 End: 09/30/25 Due: 09/30/26

A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06654947 Org: User:
Start: 01/31/25 End: 12/31/27 Due: 12/31/28

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Phase: N/A Priority: Normal
NCT ID: NCT06095167 Org: User:
Start: 01/01/24 End: 01/01/28 Due: 01/01/29

Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05922358 Org: User:
Start: 09/01/23 End: 09/01/26 Due: 09/01/27

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

Phase: N/A Priority: Normal
NCT ID: NCT05953909 Org: User:
Start: 02/01/23 End: 08/01/23 Due: 08/01/24

Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

Phase: N/A Priority: Normal
NCT ID: NCT04220528 Org: User:
Start: 12/01/19 End: 12/01/23 Due: 12/01/24

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Phase: N/A Priority: Normal
NCT ID: NCT06441045 Org: User:
Start: 10/01/24 End: 10/01/28 Due: 10/01/29

Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04149015 Org: User:
Start: 11/30/19 End: 12/31/23 Due: 12/31/24

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04121039 Org: User:
Start: 12/31/19 End: 12/31/23 Due: 12/31/24

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06786312 Org: User:
Start: 01/25/25 End: 09/25/28 Due: 09/25/29

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06692270 Org: User:
Start: 05/15/25 End: 01/10/27 Due: 01/10/28

To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Phase: N/A Priority: Normal
NCT ID: NCT04387266 Org: User:
Start: 06/01/20 End: 10/01/20 Due: 10/01/21

Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury

Phase: N/A Priority: Normal
NCT ID: NCT06325982 Org: User:
Start: 06/11/24 End: 12/31/25 Due: 12/31/26

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05751265 Org: User:
Start: 07/01/23 End: 06/01/25 Due: 06/01/26

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03486509 Org: User:
Start: 04/01/18 End: 07/01/20 Due: 07/01/21